Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

Views:
1598
Likes:
7

Views:
1598
Likes:
7
Share:

Now Playing
Part 3 | Session 1 of 4
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD
Dean J Kereiakes

Up Next
3m 53s

Part 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia
Frederick Raal
7m 19s

Part 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program
Milind Y Desai
10m 31s

Part 3 | Session 4 VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy
Milind Y Desai

Part 4 Coming Soon

13m 43s

Part 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem

29m 32s

Part 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray

18m 41s

Part 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen

17m 22s

Part 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer

16m 57s

Part 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle

22m 30s

Part 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod

Average (ratings)

No ratings

Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview	Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS	Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI	Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity	Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk	Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone	Watch now

Part 3

Expert Interviews

4 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD	Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia	Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program	Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy	Watch now

Part 4

Highlights

1 session
Coming Soon	Watch now

About the episode

AHA Conference 2024 - Long-term safety and efficacy outcomes from 48 and 72 weeks of LIB003 (LIB Therapeutics LLC) administered to patients with CVD or at high risk for CVD on oral lipid-lowering therapy (LLT) who completed one of the phase 3 base studies.

Dr Dean Kereiakes (The Ohio State University, Ohio, US) joins us onsite at AHA Conference to discuss the findings from LIBerate-OLE (NCT04798430).

LIBerate-OLE is an open-label, phase 3, extension trial investigating the use of LIB003 in patients with CVD or at high risk for CVD on LLT. Approximately 1,468 patients were enrolled in the study and were seen in the clinic for the initial 12 weeks and then every 12 weeks, with the interim doses administered at home. The primary outcome measure was the incidence of treatment-emergent adverse events after 48 and 72 weeks.

Interview Questions:
1.    What is the reasoning behind the trial?
2.    Could you tell us about the mechanism of action behind lerodalcibep?
3.    What was the study design and patient population for LIBerate-OLE?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Dean J Kereiakes

Dean J Kereiakes

Professor of Clinical Medicine

Dr Dean Kereiakes is President of The Christ Hospital Heart and Vascular Institute, Medical Director of the Christ Hospital Research Institute and Professor of Clinical Medicine at The Ohio State University.

Dr Kereiakes has been an original investigator for many interventional technologies introduced in the last two decades and has performed more than 30,000 catheterisation laboratory procedures.

He is a Fellow of the American College of Cardiology as well as The Society for Cardiovascular Angiography and Interventions.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.